China's State Council told the CFDA to establish a definite time limit for drug approvals, along with other broad initiatives for reforming the entire drug approval process; the CFDA will also ease regulations governing simultaneous China-global clinical trials of innovative drugs and allow more data from global trials; Burning Rock Biotech of Guangzhou completed a $23 million Series A+ round to advance its oncology diagnostic products; Singapore's Asian American Medical Group paid $14 million for a 60% interest in a Zhuhai outpatient medical center, Anpac Bio-Medical Science of Shanghai announced a Series A investment of several million dollars for its cancer screening technology; China's Hutchison MediPharma will continue to develop HMP-507, a small molecule anti-inflammation drug, after Janssen ended their collaboration on the drug; and BeiGene of Beijing will build a cGMP manufacturing facility in Suzhou's BioBAY for its oncology drug portfolio.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
